NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 262 filers reported holding NEKTAR THERAPEUTICS in Q2 2020. The put-call ratio across all filers is 0.72 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $18 | -28.0% | 25,310 | +130.1% | 0.00% | – |
| Q4 2022 | $25 | -99.9% | 11,000 | -1.8% | 0.00% | – |
| Q3 2022 | $36,000 | -21.7% | 11,201 | -7.7% | 0.00% | – |
| Q2 2022 | $46,000 | +666.7% | 12,141 | +964.1% | 0.00% | – |
| Q1 2022 | $6,000 | -97.0% | 1,141 | -93.6% | 0.00% | -100.0% |
| Q4 2021 | $198,000 | -35.5% | 17,805 | +4.3% | 0.00% | -50.0% |
| Q3 2021 | $307,000 | -43.6% | 17,077 | -46.1% | 0.00% | -33.3% |
| Q2 2021 | $544,000 | -32.0% | 31,697 | -20.8% | 0.00% | -40.0% |
| Q1 2021 | $800,000 | +38.4% | 39,997 | +17.6% | 0.01% | +25.0% |
| Q4 2020 | $578,000 | +21.9% | 33,997 | +19.0% | 0.00% | 0.0% |
| Q3 2020 | $474,000 | -45.8% | 28,580 | -24.2% | 0.00% | -50.0% |
| Q2 2020 | $874,000 | +140.1% | 37,716 | +84.8% | 0.01% | +100.0% |
| Q1 2020 | $364,000 | +49.2% | 20,413 | +80.4% | 0.00% | +100.0% |
| Q4 2019 | $244,000 | +38.6% | 11,313 | +17.0% | 0.00% | 0.0% |
| Q3 2019 | $176,000 | -92.5% | 9,670 | -85.4% | 0.00% | -90.9% |
| Q2 2019 | $2,359,000 | +35.9% | 66,300 | +28.3% | 0.02% | +29.4% |
| Q1 2019 | $1,736,000 | +182.7% | 51,658 | +176.7% | 0.02% | +142.9% |
| Q4 2018 | $614,000 | -82.6% | 18,669 | -67.8% | 0.01% | -78.1% |
| Q3 2018 | $3,531,000 | +704.3% | 57,924 | +543.6% | 0.03% | +540.0% |
| Q2 2018 | $439,000 | -85.4% | 9,000 | -68.1% | 0.01% | -83.9% |
| Q1 2018 | $2,997,000 | +5776.5% | 28,200 | +3217.6% | 0.03% | +3000.0% |
| Q4 2017 | $51,000 | +155.0% | 850 | 0.0% | 0.00% | – |
| Q3 2017 | $20,000 | +17.6% | 850 | 0.0% | 0.00% | – |
| Q2 2017 | $17,000 | -15.0% | 850 | 0.0% | 0.00% | – |
| Q1 2017 | $20,000 | 0.0% | 850 | -46.9% | 0.00% | – |
| Q4 2016 | $20,000 | -25.9% | 1,600 | 0.0% | 0.00% | – |
| Q3 2016 | $27,000 | +17.4% | 1,600 | 0.0% | 0.00% | – |
| Q2 2016 | $23,000 | +4.5% | 1,600 | 0.0% | 0.00% | – |
| Q1 2016 | $22,000 | – | 1,600 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Camber Capital Management LP | 2,000,000 | $67,200,000 | 3.35% |
| First Light Asset Management, LLC | 763,403 | $25,650,000 | 3.33% |
| BRIDGER MANAGEMENT, LLC | 1,238,489 | $41,613,000 | 3.29% |
| Rhenman & Partners Asset Management AB | 734,445 | $24,677,000 | 2.89% |
| BB BIOTECH AG | 2,020,676 | $67,895,000 | 1.71% |
| Gs Investments, Inc. | 54,200 | $1,821,120,000 | 1.43% |
| Artal Group S.A. | 900,000 | $30,240,000 | 1.24% |
| Cormorant Asset Management, LP | 500,000 | $16,800,000 | 1.14% |
| TOBAM | 640,547 | $21,522,000 | 1.09% |
| Bellevue Group AG | 430,026 | $14,449,000 | 0.80% |